share_log

Akebia Therapeutics (NASDAQ:AKBA) Now Covered by Analysts at StockNews.com

Akebia Therapeutics (NASDAQ:AKBA) Now Covered by Analysts at StockNews.com

木通治疗公司(纳斯达克：AKBA)现在由StockNews.com的分析师报道
Defense World ·  2022/09/20 02:12

Analysts at StockNews.com assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report issued on Tuesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

斯托克新闻网的分析师在周二发布的一份研究报告中假设了木通治疗公司(纳斯达克代码：AKBA-GET评级)的股票。该经纪公司对这家生物制药公司的股票设定了“持有”评级。

Akebia Therapeutics Stock Down 5.4 %

木通治疗类股下跌5.4%

Akebia Therapeutics stock opened at $0.36 on Tuesday. Akebia Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.35. The firm has a market capitalization of $67.09 million, a price-to-earnings ratio of -0.39 and a beta of 1.50. The firm's fifty day moving average price is $0.40 and its two-hundred day moving average price is $0.68. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

木通治疗公司的股票周二开盘报0.36美元。木通治疗公司的一年低点为0.30美元，一年高位为3.35美元。该公司市值为6709万美元，市盈率为-0.39倍，贝塔系数为1.50。该公司的50日移动均线价格为0.40美元，200日移动均线价格为0.68美元。该公司的流动比率为1.30，速动比率为1.15，债务权益比率为0.51。

Get
到达
Akebia Therapeutics
木通治疗学
alerts:
警报：

Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.54. The company had revenue of $126.76 million during the quarter, compared to the consensus estimate of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. During the same quarter in the prior year, the company posted ($0.51) earnings per share. On average, equities research analysts predict that Akebia Therapeutics will post -0.44 earnings per share for the current fiscal year.

木通治疗公司(纳斯达克代码：AKBA-GET评级)最近一次公布收益结果是在8月4日星期四。这家生物制药公司公布本季度每股收益为0.23美元，比普遍预期的每股收益(0.31美元)高出0.54美元。该公司本季度营收为1.2676亿美元，而市场普遍预期为4910万美元。木通治疗公司的净利润率为负55.04%，净资产回报率为负197.12%。去年同期，该公司公布的每股收益为0.51美元。平均而言，股票研究分析师预测，木通治疗公司本财年的每股收益将为0.44美元。

Institutional Trading of Akebia Therapeutics

木通治疗的制度性交易

Several institutional investors and hedge funds have recently made changes to their positions in AKBA. Dimensional Fund Advisors LP raised its holdings in shares of Akebia Therapeutics by 23.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,593,841 shares of the biopharmaceutical company's stock valued at $5,862,000 after purchasing an additional 498,078 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Akebia Therapeutics by 37.2% in the fourth quarter. Teacher Retirement System of Texas now owns 32,286 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 8,759 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Akebia Therapeutics during the fourth quarter worth about $30,000. Virtus ETF Advisers LLC increased its holdings in Akebia Therapeutics by 18.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 69,015 shares of the biopharmaceutical company's stock worth $156,000 after buying an additional 10,772 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Akebia Therapeutics during the first quarter worth about $75,000. Hedge funds and other institutional investors own 31.56% of the company's stock.
几家机构投资者和对冲基金最近改变了他们在akba的头寸。Dimension Fund Advisors LP在第四季度将其在木通治疗公司的股票持有量增加了23.8%。Dimension Fund Advisors LP现在拥有这家生物制药公司2,593,841股股票，价值5,862,000美元，上个季度又购买了498,078股。德克萨斯州教师退休系统第四季度增持木通治疗公司股票37.2%。德克萨斯州教师退休系统在上个季度购买了8759股后，现在拥有这家生物制药公司32,286股股票，价值73,000美元。Point72 Hong Kong Ltd在第四季度购买了木通治疗公司的新股份，价值约3万美元。Virtus ETF Advisers LLC在第四季度将其在木通治疗公司的持股增加了18.5%。Virtus ETF Advisers LLC现在拥有69,015股这家生物制药公司的股票，价值15.6万美元，上个季度又购买了10,772股。最后，Assenagon Asset Management S.A.在第一季度收购了木通治疗公司价值约7.5万美元的新股份。对冲基金和其他机构投资者持有该公司31.56%的股票。

Akebia Therapeutics Company Profile

木通治疗公司简介

(Get Rating)

(获取评级)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.

木通治疗公司是一家生物制药公司，专注于肾脏疾病患者治疗药物的开发和商业化。该公司的主要研究产品候选产品是vadustat，这是一种口服疗法，正处于第三阶段开发，用于治疗依赖透析和非透析依赖的成年患者的慢性肾脏疾病(CKD)引起的贫血。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
  • Oracle's Short-Term Pain Could Be Your Long-Term Gain
  • Lucid is Looking Like a Clear EV Winner
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • 免费获取StockNews.com关于木通治疗的研究报告(AKBA)
  • 甲骨文的短期痛苦可能是你的长期收益
  • Lucid看起来像是电动汽车的赢家
  • 仍然爱着它：投资者继续光顾麦当劳
  • 联邦快递刚刚提供了一个买入机会吗？
  • 自动区重新进入拉力赛模式，新高在望

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受木通治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对木通治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发